Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

In search of a new assay
April 2018
SHARING OPTIONS:

BOSTON—Exosome Diagnostics Inc. and Intezyne Inc. have teamed up in a collaboration agreement aimed at designing and validating a highly sensitive exosomal RNA-based assay for use in Intezyne’s Phase 1/2 clinical trials of IT-139. The assay will make use of Exosome Diagnostics’ ExoLution isolation kit and will support patient stratification and long-term monitoring. IT-139 is a novel cancer resistance pathway inhibitor for pancreatic, gastric and other cancers in combination with current anticancer therapies.
 
“As we delve further into the novel mechanism of action of IT-139, we needed a companion diagnostic assay that could reliably measure IT-139’s impact on GRP78 levels,” stated Suzanne Bakewell, Intezyne’s vice president of preclinical development. “Exosome’s cutting-edge technology has demonstrated the potential to increase the clinical utility of other products, and we are excited to collaborate with Exosome to develop a potentially groundbreaking companion diagnostic to predict treatment outcome for IT-139.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.